Skip to main content
SpringerLink
Log in

Are Busulfan-Based Preparative Regimens Equivalent, Worse, or Better than Total Body Irradiation Regimens?

  • Chapter
Current Controversies in Bone Marrow Transplantation

Part of the book series: Current Clinical Oncology ((CCO))

Abstract

There is no simple answer to the question posed in the chapter title. Comparisons of total body irradiation (TBI) and busulfan (Bu) can only be made for the methods and doses of administration that have been studied. The best Bu-based and best TBI-based regimens in specific situations have not been established. For Bu, in particular, recent developments offer promise for improved results. Further, the relative effectiveness of TBI and Bu may depend on the underlying disease, on the stage of disease, the compatibility of the donor and recipient, and on other factors, including prior therapy and co-existing medical problems. In many settings, there are advantages and disadvantages for each approach.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Jacobson L, Marks E, Robson M, et al. Effect of spleen protection on mortality following x-irradiation, J. Lab. Clin. Med., 34 (1949) 1538.

    Google Scholar 

  2. Lorenz E, Uphoff D, Reid T, et al. Modification of irradiation injury in mice and guinea pigs by bone marrow infections, J. Natl. Cancer Inst., 12 (1951) 197.

    PubMed  CAS  Google Scholar 

  3. Thomas E, Lochte H Jr, Lu W, et al. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy, N. Engl. J. Med., 257 (1957) 491.

    Article  PubMed  CAS  Google Scholar 

  4. Ferrebee J, Lochte H Jr, Jarezki A HI, et al. Successful marrow homograft in the dog after radiation, Surgery, 43 (1958) 516.

    PubMed  CAS  Google Scholar 

  5. Epstein R, Storb R, Ragde H, et al. Cytotoxic typing antisera for marrow grafting in littermate dogs, Transplantation, 6 (1968) 45–58.

    Article  PubMed  CAS  Google Scholar 

  6. Thomas E. The role of marrow transplantation in the eradication of malignant disease. Cancer 49 (1982) 1963.

    Google Scholar 

  7. Thomas E, LeBlond R, Graham T, et al. Marrow infusions in dogs given midlethal or lethal irradiation. Radiat. Res. 41 (1970) 113–124.

    Article  PubMed  CAS  Google Scholar 

  8. Mannick J, Lochte H Jr, Ashley C, et al. Autografts of bone marrow in dogs after lethal total-body radiation. Blood 15 (1960) 255.

    PubMed  CAS  Google Scholar 

  9. Cavins J, Kasakura S, Thomas E, et al. Recovery of lethally irradiated dogs following infusion of autologous marrow stored at low temperatures in dimethyl-sulphoxide. Blood 20 (1962) 730.

    PubMed  CAS  Google Scholar 

  10. Storb R and Deeg H. Failure of allogeneic canine marrow grafts after total body irradiation; allogeneic “resistance” vs transfusion induced sensitization. Transplantation 42 (1986) 571–580.

    Article  PubMed  CAS  Google Scholar 

  11. Storb R, Raff R, and Appelbaum F. Comparison of fractionated to single-dose total body irradiation in conditioning canine littermates for DLA-identical marrow grafts. Blood 74 (1991) 1139–1143.

    Google Scholar 

  12. Santos G and Owens A Jr. Syngeneic and allogeneic marrow transfusion on cyclophosphamideinduced lethality in the rat. Exp. Hematol. 10 (1966) 8–13.

    Google Scholar 

  13. Santos G and Owens A Jr. Allogeneic marrow transplantation in cyclophosphamide treated mice. Transplant Proc. 1 (1969) 44–46.

    PubMed  CAS  Google Scholar 

  14. Santos G and Owens A Jr. Syngeneic and allogeneic marrow transplants in the cyclophosphamide pretreated rat. In Dausset I, Hamgerger I, Mathe G (eds.), Advance in Transplantation. Proceedings of the First International Congress of the Transplantation Society, Paris, France, June 27–30, 1976. Munksgaard, Copenhagen, Denmark, 1968, p. 431–438.

    Google Scholar 

  15. Storb R, Buckner C, Dillingham L, et al. Cyclophosphamide regimens in Rhesus monkeys with and without marrow infusion. Cancer Res. 30 (1970) 2195–2203.

    PubMed  CAS  Google Scholar 

  16. Ford C, Micklem H, Evans P, et al. The inflow of bone marrow cells to the thymus: Studies with part body irradiated mice injected with chromosome marked bone marrow and subjected to antigenic stimulation. Ann. N.Y. Acad. Sci. 129 (1966) 283–287.

    Article  Google Scholar 

  17. Josvasen N and Boyum A. Hematopoiesis in busulfan treated mice. Scand. J. Hematol. 11 (1973) 78–86.

    Article  CAS  Google Scholar 

  18. Santos G and Tutschka P. The effect of busulfan on antibody production and skin allograft survival in the rat. J. Natl. Cancer Inst. 53 (1974) 1775–1780.

    PubMed  CAS  Google Scholar 

  19. Buckner C, Dillingham L, Giddens W Jr, et al. Toxicologic and marrow transplantation studies in rhesus monkeys given dimethylmyeran. Exp. Hematol. 3 (1975) 275–288.

    PubMed  CAS  Google Scholar 

  20. Floersheim G and Ruszkiewicz M. Bone marrow transplantation after antilymphocytic serum and lethal chemotherapy. Nature 333 (1969) 854–857.

    Article  Google Scholar 

  21. Tutschka P and Santos G. G-B incompatible bone marrow transplantation in the rat after treatment with cyclophosphamide and busulfan. Fed. Proc. 32 (1973) 226–232.

    Google Scholar 

  22. Tutschka P and Santos G. Bone marrow transplantation in the busulfan treated rat. III. Relationship between myelosuppression and immunosuppression for conditioning bone marrow recipients. Transplantation 24 (1977) 52–61.

    Article  PubMed  CAS  Google Scholar 

  23. Thomas E, Lochte H Jr., Cannon J, et al. Supralethal whole body irradiation and isologous marrow transplantation in man J. Clin. Invest. 38 (1959) 1709–1714.

    Article  PubMed  CAS  Google Scholar 

  24. Thomas E, Buckner C, Banaji M, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation and allogeneic marrow transplantation. Blood 49 (1977) 511–533.

    PubMed  CAS  Google Scholar 

  25. Bortin M. Pathogenesis of interstitial pneumonitis following allogeneic bone marrow transplantation for acute leukemia. In Gale RP (ed.), Recent Advances in Bone Marrow Transplantation. Liss, New York, 1978, pp. 445–452.

    Google Scholar 

  26. Fryer C, Fitzpatrick P, Rider W, et al. Radiation pneumonitis: experience following a large single dose of radiation. Intl. J. Rad. Oncol. Biol. Phys. 4 (1978) 931–936.

    Article  CAS  Google Scholar 

  27. Thomas E, Buckner C, Clift R, et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N. Engl. J. Med. 301 (1979) 597–599.

    Article  PubMed  CAS  Google Scholar 

  28. Thomas E, Clift R, Hersman J, et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission using fractionated or single-dose irradiation. Intl. J. Radiat. Oncol. Biol. Phys. 8 (1982) 817–821.

    Article  CAS  Google Scholar 

  29. Clift R, Buckner C, Appelbaum F, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 76 (1990) 1867–1871.

    PubMed  CAS  Google Scholar 

  30. Clift R, Buckner C, Frederick R, et al. Allogeneic transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood 77 (1991) 1660–1665.

    Google Scholar 

  31. Tutschka P, Santos G, and Elfenbein G. Marrow transplantation in acute leukemia following busulfan and cyclophosphamide. Blut. 25 (1980) 375–380.

    CAS  Google Scholar 

  32. Peters W, Henner W, Grochow L, et al. Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors. Cancer Res. 47 (1987) 6402–6406.

    PubMed  CAS  Google Scholar 

  33. Santos G, Tutschka P, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N. Engl. J. Med. 309 (1983) 1347–1353.

    Article  PubMed  CAS  Google Scholar 

  34. Tutschka P, Copelan E, and Klein J. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 70 (1987) 1382–1388.

    PubMed  CAS  Google Scholar 

  35. Copelan E, Biggs J, Thompson J, et al. Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2. Blood 78 (1991) 838–843.

    PubMed  CAS  Google Scholar 

  36. Biggs J, Szer J, Crilley P, et al. Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation following preparation with BuCy2. Blood 80 (1992) 1352–1357.

    PubMed  CAS  Google Scholar 

  37. Copelan E, Biggs J, Avalos B, et al. Radiation-free preparation for allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia. J. Clin. Oncol. 10 (1992) 237–242.

    PubMed  CAS  Google Scholar 

  38. Yeager A, Shinn C, Pardoll D, et al. Lymphoid reconstitution after transplantation of congenic hematopoietic cells in busulfan-treated mice. Blood 78 (1991) 3312–3316.

    PubMed  CAS  Google Scholar 

  39. Fishleder A, Bolwell B, and Lichtin A. Incidence of mixed chimerism using busulfan/cyclophosphamide containing regimens in allogeneic bone marrow transplantation. Bone Marrow Transplant. 9 (1992) 293–297.

    PubMed  CAS  Google Scholar 

  40. Devergie A, Blaise D, Attal M, et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxin-total body irradiation as preparative regimen: a report from The French Society of Bone Marrow Graft (SFGM). Blood 85 (1995) 2263–2268.

    PubMed  CAS  Google Scholar 

  41. Avalos B, Klein J, Kapoor N, et al. Allogeneic bone marrow transplantation following busulfan and 90 mg/kg of cyclophosphamide. Bone Marrow Transplant. 12 (1993) 655–658.

    PubMed  CAS  Google Scholar 

  42. Klein J, Avalos B, Belt P, et al. Bone marrow engraftment following unrelated donor transplantation utilizing busulfan and cyclophosphamide preparatory chemotherapy. Bone Marrow Transplant. 17 (1996) 479–483.

    PubMed  CAS  Google Scholar 

  43. Sahebi F, Copelan E, Crilley P, et al. Unrelated allogeneic bone marrow transplantation using high dose busulfan and cyclophosphamide (Bu-Cy) for the preparative regimen. Bone Marrow Transplant. 17 (1996) 685–689.

    PubMed  CAS  Google Scholar 

  44. Slattery J, Clift R, Buckner C, et al. Marrow transplantation for chronic myeloid leukemia: The influence of plasma busulfan levels on the outcome of transplantation. Blood 89 (1997) 3055–3060.

    PubMed  CAS  Google Scholar 

  45. Slattery J, Kaihorn T, McDonald G, et al. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J. Clin. Oncol. 14 (1996) 1484–1494.

    PubMed  CAS  Google Scholar 

  46. Bearman S, Appelbaum F, Buckner C, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J. Clin. Oncol. 6 (1988) 1562–1568.

    PubMed  CAS  Google Scholar 

  47. Nevill T, Barnett M, Klingemann H, et al. Regimen-related toxicity of a busulfan-cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation. J. Clin. Oncol. 9 (1991) 1224–1232.

    PubMed  CAS  Google Scholar 

  48. McDonald G, Hinds M, Fisher L, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann. Intern. Med. 118 (1993) 255–267.

    PubMed  CAS  Google Scholar 

  49. Jones R, Lee K, Beshorner W, et al. Venocclusive disease of the liver following bone marrow transplantation. Transplantation. 44 (1987) 778–783.

    Article  PubMed  CAS  Google Scholar 

  50. Morgan M, Dodds A, Atkinson K, et al. The toxicity of busulfan and cyclophosphamide as the preparative regimen for bone marrow transplantation. Br. J. Haematol. 77 (1991) 529–534.

    Article  PubMed  CAS  Google Scholar 

  51. Hartman A-R, Williams SF, and Dillon JJ. Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis. Bone Marrow Transplant. 22 (1998) 439–443.

    Article  PubMed  CAS  Google Scholar 

  52. Clift RA, Buckner CD, Thomas ED, et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 84 (1994) 2036–2043.

    PubMed  CAS  Google Scholar 

  53. Stiff P, McKenzie R, Sosman J, et al. High-dose busulfan and cyclophosphamide with bone marrow rescue for refractory Hodgkin’s disease: a tolerable and effective regimen in patients without prior nitrosourea exposure. Blood 76 (1990) 567a(Abstract).

    Google Scholar 

  54. Cunningham I, Marmaduke D, Copelan E, et al. Hyperbilirubinemia as a predictor of post-BMT mortality. Blood 78 (1991) 240a(Abstract).

    Google Scholar 

  55. Grochow L, Jones R, Brundett R, et al. Pharmacokinetics of busulfan: correlation with veno-occlusive in patients undergoing bone marrow transplantation. Cancer Chemother. Pharmacol. 25 (1989) 55–61.

    Article  PubMed  CAS  Google Scholar 

  56. Schuler US, Ehrsam M, Schneider A, et al. Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation. Bone Marrow Transplant. 22 (1998) 241–244.

    Article  PubMed  CAS  Google Scholar 

  57. Essell JH, Schroeder MT, Harman GS, et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation: a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 128 (1998) 975–981.

    PubMed  CAS  Google Scholar 

  58. Copelan E, Penza S, Pohlman B, et al. A novel Bu/CyNP-16 regimen in non-Hodgkin’s lymphoma. Blood 92 (1998) S1: 664a (Abstract).

    Google Scholar 

  59. Van Der Jagt RHC, Appelbaum F, et al. Busulfan and cyclophosphamide as a preparative regimen for bone marrow transplantation in patients with prior chest radiotherapy. Bone Marrow Transplant. 8 (1991) 211–215.

    PubMed  Google Scholar 

  60. Copelan E, Penza S, Theil K, et al. Allogeneic marrow transplantation with BuCy2 in patients with chronic myelogenous leukemia. Blood 92 S1 (1998) 285a(Abstract).

    Google Scholar 

  61. Sullivan K, Witherspoon R, Storb R, et al. Chronic graft-versus-host disease: pathogenesis, diagnosis, treatment and prognostic factors. In Baum SJ, Santos GW, and Takaku F (eds.), Recent Advances and Future Directions in Bone Marrow Transplantation, Experimental Hematology Today (1987) p. 150–157.

    Google Scholar 

  62. Bross D, Tutschka P, Farmer E, et al. Predictive factors for acute graft-versus-host disease in patients transplanted with HLA-identical bone marrow. Blood 63 (1984) 1265–1270.

    PubMed  CAS  Google Scholar 

  63. Aucouturier P, Barra A, Intator L, et al. Long-lasting IgG subclass and antibacterial polysaccharide antibody deficiency after allogeneic bone marrow transplantation. Blood 70 (1987) 779–785.

    PubMed  CAS  Google Scholar 

  64. Sheridan J, Tutschka P, Sedmak D, et al. Immunoglobulin G subclass deficiency and pneumocele infection after allogeneic bone marrow transplantation. Blood 75 (1990) 1583–1586.

    PubMed  CAS  Google Scholar 

  65. Sklar C, Kim T, and Ramsay N. Thyroid function among long-term survivors of bone marrow transplantation. Am. J. Med. 73 (1982) 688–694.

    Article  PubMed  CAS  Google Scholar 

  66. Sanders J, Buckner C, Sullivan, et al. Growth and development in children after bone marrow transplantation. Horm. Res. 30 (1988) 92–97.

    Article  PubMed  CAS  Google Scholar 

  67. Manenti F, Galimberti M, Lucarelli G, et al. Growth and endocrine function after bone marrow transplantation for thalassemia. In Buckner C, Gale R, Lucarelli G (eds.), Advances and Controversies in Thalassemia Therapy: Bone Marrow Transplantation and Other Approaches, Liss, New York, (1989) pp. 273–280.

    Google Scholar 

  68. Sanders J, and the Long-Term Follow-Up Team. Endocrine problems in children after bone marrow transplant for hematologic malignancies. Bone Marrow Transplant. 8 (1991) 2–4.

    PubMed  Google Scholar 

  69. Sanders J, and the Seattle Marrow Transplant Team. The impact of marrow transplant preparative regimens on subsequent growth and development. Semin. Hematol. 28 (1991) 244–249.

    PubMed  CAS  Google Scholar 

  70. Adan L, de Lanversin M-L, Thalassinos C, et al. Growth after bone marrow transplantation in young children conditioned with chemotherapy alone. Bone Marrow Transplant. 19 (1997) 253–256.

    Article  PubMed  CAS  Google Scholar 

  71. Wingard J Miller D, and Santos G. Testicular function after busulfan plus cyclophosphamide. J. Cell Biochem. 16A (1992) 216–225.

    Google Scholar 

  72. Copelan EA and Deeg HJ. Conditioning for allogeneic marrow transplantation in patients with lymphohematopoietic malignancies without the use of total body irradiation. Blood 80 (7) (1992) 1648–1658.

    PubMed  CAS  Google Scholar 

  73. Witherspoon R, Fisher L, and Schoh G. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N. Engl. J. Med. 321 (1989) 784–789.

    Article  PubMed  CAS  Google Scholar 

  74. Bhatia S, Ramsay N, Steinbuch M, et al. Malignant neoplasms following bone marrow transplantation. Blood 87 (1996) 3633–3639.

    PubMed  CAS  Google Scholar 

  75. Curtis R, Rowlings P, Deeg H, et al. Solid cancers after bone marrow transplantation. N. Engl. J. Med. 336 (1997) 897–904.

    Article  PubMed  CAS  Google Scholar 

  76. Copelan EA and McGuire EA. The biology and treatment of ALL in adults. Blood 85 (1995)1151–1168.

    Google Scholar 

  77. Clift R, Buckner C, and Thomas E. The treatment of acute non-lymphoblastic leukemia by allogeneic marrow transplantation. Bone Marrow Transplant. 2 (1987) 243–258.

    PubMed  CAS  Google Scholar 

  78. Report from the Working Party of Leukemia, European Group for Bone Marrow Transplantation. Allogeneic bone marrow transplantation for leukemia in Europe. Lancet. 18 (1988) 1379–1382.

    Google Scholar 

  79. McGlave P, Haake R, and Bostrom B. Allogeneic bone marrow transplantation for acute nonlymphocytic leukemia in first remission. Blood 72 (1988) 1512–1517.

    PubMed  CAS  Google Scholar 

  80. Geller R, Saral R, Piantadosi S, et al. Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia. Blood 73 (1989) 2209–2218.

    PubMed  CAS  Google Scholar 

  81. Blaise D, Maraninchi D, Archimbaud E, et al., for the Groupe d’Etude de la Greffe de Moelle Osseuse. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen. A report from the Groupe d’Etude de la Greffe de Moelle Osseuse. Blood 79 (1992) 2578–2582.

    PubMed  CAS  Google Scholar 

  82. Ringdén O, Labopin M, Tura S, et al., for the Acute Lèukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). A comparison of busulfan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Brit. J. Hematol. 93 (1996) 637–645.

    Article  Google Scholar 

  83. Gale RP, Horowitz MM, Weiner RS, et al. Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. Bone Marrow Transplant. 16 (1995) 203–208.

    PubMed  CAS  Google Scholar 

  84. Ringdén O, Ruutu T, Remberger M, et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplant Group. Blood 83 (1994) 2723–2730.

    PubMed  Google Scholar 

  85. Emanuel EJ and Patterson WB. Ethics of randomized clinical trials. J. Clin. Oncol. 16 (1998) 365–366.

    PubMed  CAS  Google Scholar 

  86. Blume K, Kenneth J, Kopecky J, et al. A prospective randomized comparison of total body irradiationetoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group Study. Blood 81 (1993) 2187–2193.

    PubMed  CAS  Google Scholar 

  87. Copelan E, Biggs J, Avalos B, et al. Radiation-free preparation for allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia. J. Clin. Oncol. 10 (1992) 237–242.

    PubMed  CAS  Google Scholar 

  88. von Bueltzingsloewen A, Esperou-Courdeau H, Souillet G, et al. Allogeneic bone marrow transplantation following busulfan-based conditioning regimen in young children with acute lymphoblastic leukemia: a cooperative study of the Societe Francaise de Greffe de Moelle. Bone Marrow Transplant. 16 (1995) 521–527.

    Google Scholar 

  89. Davis SM, Ramsay NKC, Klein JP, et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J. Clin. Oncol. (1999) in press.

    Google Scholar 

  90. Copelan EA, Grever MR, Kapoor N, et al. Marrow transplantation following busulfan and cyclophosphamide for CML in accelerated or blastic phase. Br. J. Haematol. 71 (1989) 487–491.

    Article  PubMed  CAS  Google Scholar 

  91. Ratanatharathorn V, Karanes C, Uberti J, et al. Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. Blood 81 (1993) 2194–2199.

    PubMed  CAS  Google Scholar 

  92. O’Donnell MR, Long GD, Parker PM, et al. Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. J. Clin. Oncol. 13 (1995) 2973–2979.

    PubMed  Google Scholar 

  93. Anderson JE, Appelbaum FR, Schoch G, et al. Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimen and analysis of prognostic factors. Blood 87 (1996) 51–58.

    PubMed  CAS  Google Scholar 

  94. Locatelli F, Niemeyer C, Angelucci E, et al., for the European Working Group on Myelodysplastic Syndrome in Childhood. Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: a report from the European Working Group on Myelodysplastic Syndrome in Childhood. J. Clin. Oncol. 15 (1997) 566–571.

    PubMed  CAS  Google Scholar 

  95. Lucarelli G, Polchi P, Galimberti M, et al. Bone marrow transplantation in patients with thalessemia. N. Engl. J. Med. 322 (1990) 417–421.

    Article  PubMed  CAS  Google Scholar 

  96. Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in adult thalessemia. Blood 80 (1992) 1603–1607.

    PubMed  CAS  Google Scholar 

  97. Lucarelli G, Clift RA, Galimberti M, et al. Marrow transplantation for patients with thalessemia: results in Class 3 patients. Blood 87 (1996) 2082–2088.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Edward A. Copelan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Bone Marrow Transplant Program, Department of Hematology/Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH, USA

    Brian J. Bolwell MD (Director, Staff Physician) (Director, Staff Physician)

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Copelan, E.A. (2000). Are Busulfan-Based Preparative Regimens Equivalent, Worse, or Better than Total Body Irradiation Regimens?. In: Bolwell, B.J. (eds) Current Controversies in Bone Marrow Transplantation. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-657-7_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-657-7_4

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-9812-7

  • Online ISBN: 978-1-59259-657-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation